efficacy-bg

Administered in conjunction with an oral antidepressant

SPRAVATO® demonstrated efficacy in adults with TRD and MDSI1

calender

TRD: Short-term + long-term studies1,2

Efficacy data

24-hour

MDSI: Short-term studies1

Efficacy data

 

SPRAVATO® does 
not require daily dosing

SPRAVATO® should be administered in conjunction with an oral antidepressant1

Learn more

janssen carepath

Janssen CarePath

Your one source for access, affordability, and treatment support for your patients

Learn more

callout-background

Next: What makes SPRAVATO® different?

Learn more

References:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.

2. Zaki N, Fu DJ, Daly E, et al. Long-term efficacy of esketamine nasal spray in adults with treatment-resistant depression: a subgroup analysis of the ongoing SUSTAIN-3 study. Poster presented at: Neuroscience Education Institute (NEI) Congress; November 4-7, 2021; Colorado Springs, CO.